The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes
Frontiers in Immunology · 2023
DOI: 10.3389/fimmu.2022.1096551 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, 2023. Verfasst von Man Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
The gastrointestinal tract is inhabited by trillions of commensal microorganisms that constitute the gut microbiota. As a main metabolic organ, the gut microbiota has co-evolved in a symbiotic relationship with its host, contributing to physiological homeostasis. Recent advances have provided mechanistic insights into the dual role of the gut microbiota in cancer pathogenesis. Particularly, compelling evidence indicates that the gut microbiota exerts regulatory effects on the host immune system to fight against cancer development. Some microbiota-derived metabolites have been suggested as potential activators of antitumor immunity. On the contrary, the disequilibrium of intestinal microbial communities, a condition termed dysbiosis, can induce cancer development. The altered gut microbiota reprograms the hostile tumor microenvironment (TME), thus allowing cancer cells to avoid immunosurvelliance. Furthermore, the gut microbiota has been associated with the effects and complications of cancer therapy given its prominent immunoregulatory properties. Therapeutic measures that aim to manipulate the interplay between the gut microbiota and tumor immunity may bring new breakthroughs in cancer treatment. Herein, we provide a comprehensive update on the evidence for the implication of the gut microbiota in immune-oncology and discuss the fundamental mechanisms underlying the influence of intestinal microbial communities on systemic cancer therapy, in order to provide important clues toward improving treatment outcomes in cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, China.
Förderung
- Natural Science Foundation of Shandong Province
Zitieren
APA
Wang, M., Zhang, L., Chang, W., & Zhang, Y. (2023). The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.1096551
Vancouver
Wang M, Zhang L, Chang W, Zhang Y. The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes. Frontiers in Immunology. 2023. doi:10.3389/fimmu.2022.1096551
BibTeX
@article{Wang2023,
author = {Wang, Man and Zhang, Lei and Chang, Wenguang and Zhang, Yuan},
title = {The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes},
journal = {Frontiers in Immunology},
year = {2023},
doi = {10.3389/fimmu.2022.1096551}
}
EUVIMED